February 7, 2014
A New Tide Approaches
Simeprevir and sofosbuvir both represent a further step in the evolution of more effective, less-toxic HCV treatment options. But they, too, are just the beginning. Numerous direct-acting antiretrovirals are currently moving through the latter stage of the development pipeline, suggesting that the treatment landscape by early 2015 may look as different from the present as the present does from just a few years earlier.
For the notoriously hard-to-treat HCV genotype 1 in particular, Cox states: "It's hard to predict, but right now in advanced testing, there are some combinations that are inteferon-sparing" yet have very high sustained virologic response rates -- and may not even require the use of ribavirin.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|An Airplane, a Missile, and an Unfathomable Moment in the War Against HIV|
|No Longer Cured: HIV Relapse in "Mississippi Child" Raises New Questions|
|I'm an HIV Physician. And I'm Starting PrEP. A Blog Entry by Howard Grossman, M.D.|
|Coverage of AIDS 2014: The 20th International AIDS Conference|
|AIDS 2014 to Focus on Scaling Up What Works|
|Amidst Sadness, AIDS 2014 to Proceed as Global HIV Community Mourns Lost Leaders|